Chularat Hospital vs Tenet Healthcare: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chularat Hospital Public Company Limited (CHG.BK)

Q3 202620 Jul – 5 Oct 2026

▲2▼1

Hospital sector swings from sell to buy as SSO rate decision looms

Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded CHG to sell, warning that 16 new premium clinics inside public hospitals will steal middle-income and foreign patients, sparking price wars, higher marketing costs, doctor poaching and tougher insurer bargaining. That squeezes CHG's revenue and margins, pushing the stock down.
This is the main negative force on CHG this period, directly cutting its earnings estimates and rating.
KKPS turns overweight on hospitals, buy CHG at 2 baht KKPS upgraded the hospital sector to overweight and rated CHG a buy with a 2 baht target. It argues government budget limits will push state health costs onto private hospitals, adding over 100 billion baht of potential revenue, while sector earnings have passed their trough and trade cheaply versus regional peers.
This is the strongest new positive catalyst, reversing the earlier sell call and giving a concrete upside target.
SSO service-rate decision pending; CHG rated hold Kasikorn Securities said a delay in electing the Social Security Office board won't stop a review of medical service rates, with a key meeting on October 5. It rates CHG a hold with a 1.69 baht target, noting that if SSO doesn't raise rates at all, CHG's value would fall about 4%.
This is the key regulatory swing factor for CHG's revenue, with a clear downside if the rate rise fails.
Maybank and Yuanta name CHG a top pick on stable revenue Maybank raised its 2026 SET target and named CHG a top hospital pick, citing stable revenue and specific supporting factors. Yuanta then flagged CHG among stocks with strong third-quarter profit momentum, helped by domestic and tourism recovery from a low 2025 base.
These broker endorsements add fresh demand-side support and reinforce the positive turn in sentiment.

August 202620 Jul – 5 Oct 2026

▲2▼1

Hospital sector swings from sell to buy as SSO rate decision looms

Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded CHG to sell, warning that 16 new premium clinics inside public hospitals will steal middle-income and foreign patients, sparking price wars, higher marketing costs, doctor poaching and tougher insurer bargaining. That squeezes CHG's revenue and margins, pushing the stock down.
This is the main negative force on CHG this period, directly cutting its earnings estimates and rating.
KKPS turns overweight on hospitals, buy CHG at 2 baht KKPS upgraded the hospital sector to overweight and rated CHG a buy with a 2 baht target. It argues government budget limits will push state health costs onto private hospitals, adding over 100 billion baht of potential revenue, while sector earnings have passed their trough and trade cheaply versus regional peers.
This is the strongest new positive catalyst, reversing the earlier sell call and giving a concrete upside target.
SSO service-rate decision pending; CHG rated hold Kasikorn Securities said a delay in electing the Social Security Office board won't stop a review of medical service rates, with a key meeting on October 5. It rates CHG a hold with a 1.69 baht target, noting that if SSO doesn't raise rates at all, CHG's value would fall about 4%.
This is the key regulatory swing factor for CHG's revenue, with a clear downside if the rate rise fails.
Maybank and Yuanta name CHG a top pick on stable revenue Maybank raised its 2026 SET target and named CHG a top hospital pick, citing stable revenue and specific supporting factors. Yuanta then flagged CHG among stocks with strong third-quarter profit momentum, helped by domestic and tourism recovery from a low 2025 base.
These broker endorsements add fresh demand-side support and reinforce the positive turn in sentiment.

Latest20 Jul – 5 Oct 2026

▲2▼1

Hospital sector swings from sell to buy as SSO rate decision looms

Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded CHG to sell, warning that 16 new premium clinics inside public hospitals will steal middle-income and foreign patients, sparking price wars, higher marketing costs, doctor poaching and tougher insurer bargaining. That squeezes CHG's revenue and margins, pushing the stock down.
This is the main negative force on CHG this period, directly cutting its earnings estimates and rating.
KKPS turns overweight on hospitals, buy CHG at 2 baht KKPS upgraded the hospital sector to overweight and rated CHG a buy with a 2 baht target. It argues government budget limits will push state health costs onto private hospitals, adding over 100 billion baht of potential revenue, while sector earnings have passed their trough and trade cheaply versus regional peers.
This is the strongest new positive catalyst, reversing the earlier sell call and giving a concrete upside target.
SSO service-rate decision pending; CHG rated hold Kasikorn Securities said a delay in electing the Social Security Office board won't stop a review of medical service rates, with a key meeting on October 5. It rates CHG a hold with a 1.69 baht target, noting that if SSO doesn't raise rates at all, CHG's value would fall about 4%.
This is the key regulatory swing factor for CHG's revenue, with a clear downside if the rate rise fails.
Maybank and Yuanta name CHG a top pick on stable revenue Maybank raised its 2026 SET target and named CHG a top hospital pick, citing stable revenue and specific supporting factors. Yuanta then flagged CHG among stocks with strong third-quarter profit momentum, helped by domestic and tourism recovery from a low 2025 base.
These broker endorsements add fresh demand-side support and reinforce the positive turn in sentiment.

Tenet Healthcare Corporation (THC)

Q3 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

August 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

Latest21 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.